ATE540677T1 - S-triazolyl alpha mercaptoacetanilide als hemmer der reversen transkriptase von hiv - Google Patents

S-triazolyl alpha mercaptoacetanilide als hemmer der reversen transkriptase von hiv

Info

Publication number
ATE540677T1
ATE540677T1 AT05790722T AT05790722T ATE540677T1 AT E540677 T1 ATE540677 T1 AT E540677T1 AT 05790722 T AT05790722 T AT 05790722T AT 05790722 T AT05790722 T AT 05790722T AT E540677 T1 ATE540677 T1 AT E540677T1
Authority
AT
Austria
Prior art keywords
hiv
reverse transcriptase
mercaptoacetanilide
inhibitor
triazolyl
Prior art date
Application number
AT05790722T
Other languages
English (en)
Inventor
Jean-Luc Girardet
Yung-Hyo Koh
La Rosa Martha De
Esmir Gunic
Zhi Hong
Stanley Lang
Hong Kim
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36000576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE540677(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Application granted granted Critical
Publication of ATE540677T1 publication Critical patent/ATE540677T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Road Signs Or Road Markings (AREA)
  • Pens And Brushes (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT05790722T 2004-08-25 2005-08-25 S-triazolyl alpha mercaptoacetanilide als hemmer der reversen transkriptase von hiv ATE540677T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60422004P 2004-08-25 2004-08-25
US60421904P 2004-08-25 2004-08-25
US68635105P 2005-05-31 2005-05-31
PCT/US2005/030259 WO2006026356A2 (en) 2004-08-25 2005-08-25 S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE

Publications (1)

Publication Number Publication Date
ATE540677T1 true ATE540677T1 (de) 2012-01-15

Family

ID=36000576

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09170772T ATE528001T1 (de) 2004-08-25 2005-08-25 S-triazolyl-alpha-mercaptoacetanilide als inhibitoren von hiv-umkehrtranskriptase
AT05790722T ATE540677T1 (de) 2004-08-25 2005-08-25 S-triazolyl alpha mercaptoacetanilide als hemmer der reversen transkriptase von hiv

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT09170772T ATE528001T1 (de) 2004-08-25 2005-08-25 S-triazolyl-alpha-mercaptoacetanilide als inhibitoren von hiv-umkehrtranskriptase

Country Status (31)

Country Link
US (8) US7947721B2 (de)
EP (5) EP2402011B1 (de)
JP (2) JP4952943B2 (de)
KR (1) KR101241716B1 (de)
CN (2) CN101817793B (de)
AT (2) ATE528001T1 (de)
AU (2) AU2005280130C9 (de)
BR (2) BRPI0514630B8 (de)
CA (1) CA2578068C (de)
CY (2) CY1112221T1 (de)
DK (1) DK2135608T3 (de)
EA (2) EA015846B1 (de)
EC (1) ECSP077322A (de)
ES (2) ES2380604T3 (de)
FR (1) FR16C0031I2 (de)
HR (1) HRP20130075T1 (de)
HU (1) HUS1600034I1 (de)
IL (3) IL181523A (de)
IN (1) IN2014CN03762A (de)
LT (1) LTC2135608I2 (de)
LU (1) LU93169I2 (de)
ME (1) ME01512B (de)
MX (1) MX2007002236A (de)
NL (1) NL300825I2 (de)
NZ (2) NZ581376A (de)
PL (1) PL2135608T3 (de)
PT (1) PT2135608E (de)
RS (1) RS52632B (de)
SG (2) SG185992A1 (de)
SI (1) SI2135608T1 (de)
WO (1) WO2006026356A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2402011B1 (de) 2004-08-25 2012-11-14 Ardea Biosciences, Inc. S-Triazolyl-Alpha-Mercaptoacetanilide als Hemmer der reversen Transkriptase von HIV
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
CA2687747C (en) 2007-05-30 2015-11-17 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
WO2009030996A1 (en) * 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
EA201270666A1 (ru) * 2007-11-27 2012-12-28 Ардеа Биосайнсиз Инк. Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
JP2012502050A (ja) * 2008-09-04 2012-01-26 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及びそれを使用する方法。
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
EP2349258A1 (de) * 2008-10-24 2011-08-03 Ardea Biosciences, Inc. Zusammensetzungen mit 4- (2- ( 5-brom-4- ( l-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triazol-3-ylthio) acetamido -3-chlorbenzoesäure und pharmazeutisch annehmbare salze davon
WO2010048592A1 (en) * 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
EP2432468A2 (de) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Verfahren zur modulierung des harnsäurespiegels
CN102040546B (zh) * 2009-10-10 2014-10-15 台州市华南医化有限公司 一种4-环丙基-1-异硫氰基萘的制备方法及中间体4-环丙基-1-萘甲醛肟/卤化物
MX2012007925A (es) * 2010-01-08 2012-08-03 Ardea Biosciences Inc Formas polimorficas, cristalinas y de mesofase de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-ilti o)acetato de sodio, y usos de las mismas.
US9402827B2 (en) 2010-03-30 2016-08-02 Ardea Biosciences, Inc. Treatment of gout
ES2670700T3 (es) 2010-06-15 2018-05-31 Ardea Biosciences, Inc. Tratamiento de gota e hiperuricemia
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
EP2582664A4 (de) 2010-06-16 2014-07-09 Ardea Biosciences Inc Phenylthioacetatverbindungen und -zusammensetzungen sowie verfahren zu ihrer verwendung
CN101899013B (zh) * 2010-07-12 2012-07-25 山东大学 2-(2-取代芳基-2h-1,2,4-三唑-3-巯基)乙酰胺衍生物及其制备方法与应用
EP2627331A4 (de) * 2010-10-15 2014-03-12 Ardea Biosciences Inc Verfahren zur behandlung von hyperurikämie und damit zusammenhängenden erkrankungen
MX2013007505A (es) 2010-12-30 2013-08-01 Ardea Biosciences Inc Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1 -il)-4h-1,2,4-triazol-3-iltio)acetico y usos de los mismos.
UA114304C2 (uk) 2011-11-03 2017-05-25 Ардеа Біосайєнсіс, Інк. Спосіб зниження сироваткових рівнів сечової кислоти у людини
AR091651A1 (es) * 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
WO2014198241A1 (en) * 2013-06-14 2014-12-18 Sunshine Lake Pharma Co., Ltd. Thio-1,2,4-triazole derivatives and method for preparing the same
CN103524440B (zh) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
WO2015075561A2 (en) * 2013-11-22 2015-05-28 Crystal Pharmatech Co., Ltd. Crystalline forms of lesinurad and its sodium salt
CN104557748A (zh) * 2014-01-25 2015-04-29 广东东阳光药业有限公司 硫代-1,2,4-三唑衍生物的新的固体形态
CN105315218A (zh) * 2014-07-17 2016-02-10 天津药物研究院 一种制备lesinurad中间体1-萘基三唑硫酮的方法
CN104341363B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104341361B (zh) * 2014-10-27 2017-01-11 张远强 一种腈基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104326998B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104326993B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104311498B (zh) * 2014-10-27 2016-04-06 张远强 烷氧基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104341362B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104327000B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104370842B (zh) * 2014-10-27 2016-07-13 张远强 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104370841B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
EP3112334A1 (de) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Verfahren zur herstellung von 1-cyclopropyl-naphthalenen
CN104987311A (zh) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 一种[4-(4-环丙基萘-1-基)-5-硝基- 4h-[1,2,4]三唑-3-基硫烷基]-乙酸乙酯的制备方法及其中间体(5-硝基-4h-[1,2,4]三唑-3-基硫基)-乙酸乙酯
CN105153056A (zh) * 2015-07-01 2015-12-16 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
CN105017168A (zh) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
WO2017036884A1 (en) 2015-08-28 2017-03-09 Sandoz Ag A lesinurad, free form / lesinurad ethyl ester co-crystal
CN105566237B (zh) * 2016-03-01 2018-05-18 山东大学 一种治疗痛风的三唑巯乙酸类化合物的制备方法
WO2017215589A1 (zh) * 2016-06-17 2017-12-21 南京明德新药研发股份有限公司 一种卤代化合物及其轴手性异构体
EP3281941B1 (de) 2016-08-11 2019-07-24 Zentiva K.S. Verfahren zur herstellung von 2-(5-brom-4-(1-cyclopropylnaphthalin-4-yl)-4h-1,2,4-triazol-3-ylthio)essigsäure
EP3372592A1 (de) 2017-03-07 2018-09-12 Zentiva, k.s. Feste formen von lesinurad aminsälze
US10351537B2 (en) * 2017-03-10 2019-07-16 Apotex Inc. Processes for the preparation of lesinurad and intermediates thereof
EP3315494A1 (de) 2017-04-19 2018-05-02 Química Sintética, S.A. Amorphe form von lesinurad und verfahren zu deren herstellung
CN108947919B (zh) 2017-05-17 2023-05-02 上海奥博生物医药股份有限公司 一种抗痛风药Lesinurad的新型制备方法及其关键中间体
WO2019001325A1 (zh) * 2017-06-28 2019-01-03 苏州科睿思制药有限公司 雷西纳得的晶型xv及其制备方法
EP3498697A1 (de) 2017-12-12 2019-06-19 Química Sintética, S.A. Neuartige salze und polymorphe von lesinurad
JP7728864B2 (ja) 2021-05-28 2025-08-25 住友化学株式会社 シクロアルキルブロミドの製造方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2009A (en) * 1841-03-18 Improvement in machines for boring war-rockets
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
US226186A (en) 1880-04-06 Car-coupling
JPS5641637B2 (de) 1973-11-26 1981-09-29
US6832996B2 (en) * 1995-06-07 2004-12-21 Arthrocare Corporation Electrosurgical systems and methods for treating tissue
JPH07215940A (ja) 1994-01-27 1995-08-15 Torii Yakuhin Kk 抗ウイルス活性を有する化合物
WO1998035957A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6245817B1 (en) * 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
JPH10243033A (ja) * 1997-02-28 1998-09-11 Oki Electric Ind Co Ltd 復調装置
DE69943247D1 (de) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
JP2002529469A (ja) 1998-11-12 2002-09-10 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれに関する方法
WO2000037471A1 (en) * 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: gaba brain receptor ligands
PL348596A1 (en) * 1998-12-25 2002-06-03 Shionogi & Co Aromatic heterocycle compounds having hiv integrase inhibiting activities
US6593077B2 (en) * 1999-03-22 2003-07-15 Special Materials Research And Technology, Inc. Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate
KR100638954B1 (ko) 2001-03-02 2006-10-25 스미스클라인 비참 코포레이션 역전사 효소 억제제로서의 벤조페논
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AU2003222648A1 (en) 2002-05-13 2003-12-02 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
AU2003295324B2 (en) * 2002-08-23 2008-08-28 Ardea Biosciences,Inc. Non-nucleoside reverse transcriptase inhibitors
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
US20070021449A1 (en) 2003-02-07 2007-01-25 Jan Heeres Pyrimidine derivatives for the prevention of hiv infection
DE602004031641D1 (de) 2003-09-25 2011-04-14 Janssen Pharmaceutica Nv Die replikation von hiv hemmende purinderivate
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
US7517998B2 (en) 2004-06-01 2009-04-14 Boehringer Ingelheim International Gmbh Non nucleoside reverse transcriptase inhibitors
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
EP2402011B1 (de) * 2004-08-25 2012-11-14 Ardea Biosciences, Inc. S-Triazolyl-Alpha-Mercaptoacetanilide als Hemmer der reversen Transkriptase von HIV
EA201270666A1 (ru) * 2007-11-27 2012-12-28 Ардеа Биосайнсиз Инк. Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
WO2010048592A1 (en) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
EP2349258A1 (de) 2008-10-24 2011-08-03 Ardea Biosciences, Inc. Zusammensetzungen mit 4- (2- ( 5-brom-4- ( l-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triazol-3-ylthio) acetamido -3-chlorbenzoesäure und pharmazeutisch annehmbare salze davon
TWM377707U (en) * 2009-09-16 2010-04-01 Nat Energy Technology Co Ltd Assembly of power supply

Also Published As

Publication number Publication date
CN101817793B (zh) 2014-01-08
US8481581B2 (en) 2013-07-09
NZ553534A (en) 2010-10-29
SG185992A1 (en) 2012-12-28
JP2012077088A (ja) 2012-04-19
US8003681B2 (en) 2011-08-23
BRPI0514630B8 (pt) 2021-05-25
LTC2135608I2 (lt) 2017-07-25
EA015846B1 (ru) 2011-12-30
LU93169I2 (fr) 2016-10-10
WO2006026356A3 (en) 2006-08-10
AU2009217458A8 (en) 2009-10-29
EP2402011B1 (de) 2012-11-14
EP1789039A2 (de) 2007-05-30
RS52632B (sr) 2013-06-28
CA2578068C (en) 2011-08-09
KR20070054694A (ko) 2007-05-29
EP2135608B1 (de) 2011-10-12
CY1112221T1 (el) 2015-12-09
PL2135608T3 (pl) 2012-07-31
AU2005280130C1 (en) 2010-02-18
JP4952943B2 (ja) 2012-06-13
EP2135608A1 (de) 2009-12-23
BRPI0514630B1 (pt) 2020-09-15
EP1789039B1 (de) 2012-01-11
HUS1600034I1 (hu) 2016-09-28
ECSP077322A (es) 2007-04-26
BRPI0520870B1 (pt) 2020-11-10
US20100069645A1 (en) 2010-03-18
IL181523A0 (en) 2007-07-04
CN101817793A (zh) 2010-09-01
ME01512B (me) 2014-04-20
NL300825I2 (de) 2017-01-24
US20110190491A1 (en) 2011-08-04
CY2016028I1 (el) 2016-12-14
JP5457472B2 (ja) 2014-04-02
WO2006026356A2 (en) 2006-03-09
LTPA2016024I1 (lt) 2016-09-12
ES2380604T3 (es) 2012-05-16
US8946273B2 (en) 2015-02-03
AU2005280130B2 (en) 2009-09-10
ATE528001T1 (de) 2011-10-15
US20080176850A1 (en) 2008-07-24
AU2005280130C9 (en) 2010-03-04
US20120283301A1 (en) 2012-11-08
US20180002296A1 (en) 2018-01-04
EP2402011A1 (de) 2012-01-04
CN101083987A (zh) 2007-12-05
US20110313157A1 (en) 2011-12-22
PT2135608E (pt) 2012-01-13
US20100267724A2 (en) 2010-10-21
DK2135608T3 (da) 2012-01-23
ES2374773T3 (es) 2012-02-21
CY2016028I2 (el) 2016-12-14
EP2609917A1 (de) 2013-07-03
EP2433633A1 (de) 2012-03-28
CN101083987B (zh) 2011-01-26
BRPI0520870B8 (pt) 2021-05-25
HK1133582A1 (en) 2010-04-01
FR16C0031I2 (fr) 2017-03-31
EP1789039A4 (de) 2009-08-05
JP2008510828A (ja) 2008-04-10
CA2578068A1 (en) 2006-03-09
KR101241716B1 (ko) 2013-03-08
NZ581376A (en) 2011-05-27
US20100081827A1 (en) 2010-04-01
AU2009217458B2 (en) 2009-11-19
BRPI0514630A (pt) 2008-06-17
AU2009217458A1 (en) 2009-10-15
US20150094284A1 (en) 2015-04-02
EP2135608B8 (de) 2012-03-21
IL219131A0 (en) 2012-06-28
MX2007002236A (es) 2007-07-09
IL201546A (en) 2013-10-31
EA200901186A1 (ru) 2010-04-30
US8252828B2 (en) 2012-08-28
EA200700488A1 (ru) 2007-08-31
US7947721B2 (en) 2011-05-24
IN2014CN03762A (de) 2015-09-25
SI2135608T1 (sl) 2012-03-30
FR16C0031I1 (de) 2016-09-23
AU2005280130A1 (en) 2006-03-09
SG155246A1 (en) 2009-09-30
IL181523A (en) 2013-12-31
EA014737B1 (ru) 2011-02-28
HRP20130075T1 (hr) 2013-02-28

Similar Documents

Publication Publication Date Title
ATE540677T1 (de) S-triazolyl alpha mercaptoacetanilide als hemmer der reversen transkriptase von hiv
BR0309557A (pt) Inibidores da transcriptase reversa não nucleosìdeos
ATE494893T1 (de) Sulfonamide, sulfamate und sulfamide als gamma- secretase-hemmer
TR200402535T4 (tr) Serin proteaz inhibitörleri.
ATE373005T1 (de) Thienopyrrole als antivirale mittel
IS7337A (is) Nikótínamíð afleiður nytsamlegar sem P38 hindrar
EP1771454A4 (de) Peptidanaloga als hepatitis c-hemmer
DE60113412D1 (de) Inhibitoren von serin proteasen
ATE356130T1 (de) Inhibitoren von cruzipain und anderen cysteinproteasen
ATE368645T1 (de) Aminosäurederivate als hiv-protease-inhibitoren
ECSP077130A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de náuseas y vómitos
ECSP077380A (es) Mezclas de agentes tensioactivos y de disolventes
ATE407937T1 (de) Rutheniumkomplexe mit antikrebswirkung
EA200602281A1 (ru) Гетероарилсульфоны и сульфонамиды и их терапевтические применения
EA200601855A1 (ru) Гербицидоактивные 3-амино-2-тиометилбензоилпиразолы
BRPI0412446A (pt) compostos de silicio e seu uso
EA200701692A1 (ru) Ингибиторы протеазы вич
DE60239924D1 (de) Cyclopropaheterocyclen als nicht-nukleosidische hemmer der reversen transkriptase
ATE412005T1 (de) Zyklosporinanalog
RU2007122284A (ru) Предотвращениеи вертикальных инфекций, вызываемых эндопаразитами
DE60206782D1 (de) Substituierte amide, sulfonamide und harnstoffe mit kinasehemmender wirkung
UA89200C2 (ru) S-ТРИАЗОЛИЛ-б-МЕРКАПТОАЦЕТАНИЛИДЫ КАК ИНГИБИТОРЫ ОБРАТНОЙ ТРАНСКРИПТАЗЫ ВИЧ
DE60326035D1 (de) Dipyridodiazepinone als inhibitoren der reversen transkriptase
TR200401430U (tr) Yekpare takma halkalı fular
DE50301462D1 (de) (Tief)Kühltruhe